Welcome to PsychU!

Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Re-Imagining The Dopamine Hypothesis Of Schizophrenia: How Can We Find A Balance?

The dopamine hypothesis of schizophrenia has been foundational in elucidating the benefit of dopamine-blocking actions of antipsychotic medications over the past 60 years. Although blocking the D2 receptors may lead to positive symptom-alleviation in schizophrenia, doing so may come at a great cost to the overall well-being of individuals with severe mental illness. This webinar will feature two experts in the field of schizophrenia, who will speak to opportunities and challenges of currently available antipsychotics with a glimpse of the future.



Christoph Correll, MD

Professor of Psychiatry and Molecular Medicine; The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; Professor and Chair​; Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy​; Charité University Medicine Berlin​, Berlin, Germany

Professor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.

William Wirshing, MD

Clinical Professor of Psychiatry, Keck USC School of Medicine; and Medical Director of Exodus Recovery, Inc. in Los Angeles, CA

Dr. William Wirshing is a Clinical Professor of Psychiatry at the Keck USC School of Medicine and Medical Director of Exodus Recovery, Inc in Los Angeles, where he provides psychiatric and chemical dependency care. His 40-year career has focused on the treatment of persons with schizophrenia and in particular the toxic consequences of putative antipsychotic compounds. Dr. Wirshing and his co-investigators at UCLA and the West Los Angeles VA Medical Center, pioneered the early studies leading to the discovery of metabolic side effects that became a veritable hallmark of the newer class of agents. His findings led to the development of the American Psychiatric Association and American Diabetes Association consensus guideline to appropriately monitor patients on atypical antipsychotic agents.

Laura Brennan, PhD (OPDC)

Clinical & Scientific Liaison

Speakers Christoph Correll and William Wirshing, are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. 
Speaker Laura Brennan is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. 


Log in to register

Already registered?

Already registered?

Use this tool to manage your registration.

Related Resources